EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mismatch repair deficiency drives malignant progression and alters the tumor immune microenvironment in glioblastoma models

Montserrat Puigdelloses Vallcorba, Nishant Soni, Seung-Won Choi, Kavita Rawat, Tanvi Joshi, Sam Friedman, Alice Buonfiglioli, Angelo Angione, Zhihong Chen, Gonzalo Piñero, Gabrielle Price, Mehek Dedhia und 13 weitere

Journal of Clinical Investigation · 2026

DOI: 10.1172/jci195189 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Montserrat Puigdelloses Vallcorba und 24 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Oncological Sciences and Neurosurgery, The Tisch Cancer Institute and. Hauptthemen laut MEDLINE: Glioblastoma, Tumor Microenvironment, DNA Mismatch Repair, Brain Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Tisch cancer Institute, NIH/NINDS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations in DNA mismatch repair (MMR) pathway genes ( MSH2 , MSH6 , MLH1 , and PMS2 ) are linked to acquired resistance to temozolomide (TMZ) and high tumor mutation burden (TMB) in high-grade gliomas (HGGs), including glioblastomas (GBMs). However, the specific roles of individual MMR genes in the initiation, progression, TMB, microsatellite instability (MSI), and resistance to TMZ in gliomas remain unclear. Here, we developed de novo mouse models of germline and somatic MMR-deficient (MMRd) HGGs. Surprisingly, loss of Msh2 or Msh6 did not lead to high TMB, MSI, nor did it confer a response to anti–programmed cell death 1 (anti–PD-1) in GBM. Similarly, human GBM showed discordance between MMR gene mutations and the TMB and MSI. Germline MMRd promoted the progression from low-grade to HGG and reduced survival compared with MMR-proficient (MMRp) tumor–bearing mice. This effect was not tumor cell intrinsic but was associated with MMRd in the tumor immune microenvironment, driving immunosuppressive myeloid programs, reduced lymphoid infiltration, and CD8 + T cell exhaustion. Both MMR-reduced (MMRr) and MMRd GBM were resistant to TMZ, unlike MMRp tumors. Our study shows that N 3 -(2-fluoroethyl) imidazotetrazine (KL-50), an imidazotetrazine-based DNA targeting agent that induces MMR-independent cross-link–mediated cytotoxicity, was effective against germline and somatic MMRr and MMRd GBMs, offering a potential therapy for TMZ-resistant HGG with MMR alterations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaTumor MicroenvironmentDNA Mismatch RepairBrain NeoplasmsAnimalsMiceHumansMutS Homolog 2 ProteinDisease Models, AnimalDisease ProgressionDNA-Binding ProteinsTemozolomideDrug Resistance, NeoplasmMice, KnockoutFemaleNeoplastic Syndromes, HereditaryColorectal Neoplasms

Stichwörter der Autor:innen

Brain cancerCell biologyDNA repairImmunologyImmunotherapyNeuroscienceOncology

Substanzen

MutS Homolog 2 ProteinDNA-Binding ProteinsTemozolomideG-T mismatch-binding proteinMSH2 protein, humanMsh2 protein, mouse

Autor:innen und Institutionen

  • Departments of Oncological Sciences and Neurosurgery, The Tisch Cancer Institute and.
  • Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Departments of Systems Biology and Biomedical Informatics, Columbia University, New York, New York, USA.
  • Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Yale Center for Research Computing, Yale School of Medicine, New Haven, Connecticut, USA.
  • Human Immune Monitoring Center and.

Förderung

  • NCI NIH HHS
  • Tisch cancer Institute
  • NIH/NINDS
  • NIH/NCI
  • NIH

Zitieren

APA

Puigdelloses Vallcorba, M., Soni, N., Choi, S. W., Rawat, K., Joshi, T., Friedman, S., Buonfiglioli, A., Angione, A., Chen, Z., Piñero, G., Price, G., Dedhia, M., Roche, R., Radkevich, E., Bowcock, A. M., Bhatt, D., Edelmann, W., Samstein, R. M., Richardson, T. E., …, & Hambardzumyan, D. (2026). Mismatch repair deficiency drives malignant progression and alters the tumor immune microenvironment in glioblastoma models. Journal of Clinical Investigation. https://doi.org/10.1172/jci195189

Vancouver

Puigdelloses Vallcorba M, Soni N, Choi SW, Rawat K, Joshi T, Friedman S, et al. Mismatch repair deficiency drives malignant progression and alters the tumor immune microenvironment in glioblastoma models. Journal of Clinical Investigation. 2026. doi:10.1172/jci195189

BibTeX
@article{PuigdellosesVallcorba2026,
  author = {Puigdelloses Vallcorba, Montserrat and Soni, Nishant and Choi, Seung-Won and Rawat, Kavita and Joshi, Tanvi and Friedman, Sam and Buonfiglioli, Alice and Angione, Angelo and Chen, Zhihong and Piñero, Gonzalo and Price, Gabrielle and Dedhia, Mehek and Roche, Raina and Radkevich, Emir and Bowcock, Anne M and Bhatt, Deepti and Edelmann, Winfried and Samstein, Robert M and Richardson, Timothy E and Tsankova, Nadejda M and Tsankov, Alexander M and Bindra, Ranjit S and Rabadan, Raul and Vasquez, Juan C and Hambardzumyan, Dolores},
  title = {Mismatch repair deficiency drives malignant progression and alters the tumor immune microenvironment in glioblastoma models},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1172/jci195189}
}
Kostenlos starten →